Implementation & Service Delivery

Implementation and service delivery is not a condition or a treatment; it is the unglamorous, decisive question of how a psychedelic therapy actually reaches people once the trials are done. A successful trial answers "does this work in a controlled setting?". This page is about everything that comes after: who provides the therapy, how they are trained and supervised, whether people are treated one at a time or in groups, what kind of clinic or service is needed, how it slots into a health system, and what the whole thing costs. These are not afterthoughts. They determine whether a promising treatment becomes a real option for ordinary patients or stays a boutique intervention for the few.

This is also one of the field’s most genuinely unsolved areas, and an honest page has to treat it as emerging rather than established. The evidence here is not efficacy trials but implementation studies, service-model proposals, workforce analyses, cost projections and a small number of real-world programmes. Much of it is description and argument about how delivery might work, with relatively little hard data on how it actually does. The field is, in effect, building the aeroplane while flying it.

The single most important idea to carry through this page is that the drug is the easy part and the therapy is the hard part. A dose of psilocybin or ketamine is cheap and simple; the hours of skilled human preparation, support and integration around it are expensive, labour-intensive and difficult to standardise. That is why delivery is so much harder than efficacy, and why the questions on this page, about workforce, cost, fidelity and access, are inseparable from the questions of health economics and public health covered elsewhere. How to provide this well, to many, affordably, is the bottleneck the whole field now faces.

Because there is no condition here, the relevant "current practice" is the small and uneven set of real-world delivery models. The clearest reality is that ketamine, not the classic psychedelics, is what is actually being delivered at scale: it has the only genuine real-world clinical dataset on the page, an academic-clinic programme treating a comorbid, messy real-world population quite unlike a trial sample[1]J Affect Disord (2017), first published real-world ketamine TRD programme (41 patients, 73% comorbid): 24h response 53.7%, remission 41.5% (retrospective, uncontrolled). The classic psychedelics exist in delivery only in a few regulated settings, Oregon’s licensed psilocybin services, Australia’s authorised-prescriber access to psilocybin and MDMA, and emerging models such as a proposed NHS pathway for psilocybin[2]Br J Psychiatry (2026), NHS implementation model for psilocybin: support must be available not only to those who can pay but to all on an equitable basis, but with almost no published outcome or throughput data.

What the real-world picture mostly reveals is a large gap between how psychedelics are used and how clinical care imagines them. Surveys find that most use happens far outside the clinic: the great majority of users never discuss it with their doctor, and only a tiny fraction use in a clinical setting[3]J Psychoactive Drugs (2022), naturalistic-use survey: 72.5% never discussed psychedelic use with their primary-care provider and only 3% used in a clinical setting, even as the public broadly supports supervised, licensed provision[4]AJOB Neuroscience (2024), nationally representative US survey (n=795): strong bipartisan support for supervised, licensed psilocybin use. So the "standard" of delivery is really two disconnected worlds, a small, intensive clinical model and a large, unsupervised naturalistic one, and much of implementation science is about how, or whether, to bridge them, including by using pragmatic trials and real-world data rather than relying on confirmatory trials alone[5]J Psychopharmacol (2021), argues for supplementing confirmatory trials with pragmatic trials, real-world data and digital health to find optimal delivery protocols.

The defining problem for the field’s future is the workforce, and the most-discussed answer is group delivery. The arithmetic is stark: providing one-to-one psychedelic therapy to everyone who might benefit would require a trained workforce far larger than exists. A widely cited cost model found that group delivery could save roughly half the clinician cost for MDMA-assisted therapy and a third for psilocybin, freeing thousands of clinician-years[1]Front Psychiatry (2023), group-therapy cost model: group delivery saved 50.9% of clinician costs for MDMA-PTSD and 34.7% for psilocybin-MDD, needing thousands fewer clinicians (a projection). Early group programmes, such as the HOPE psilocybin-group model for cancer patients[2]J Psychedelic Studies (2023), HOPE group-psilocybin feasibility: cohorts of 4-6 with group preparation, a single 25 mg group session and group integration, are testing whether this is feasible in practice.

The honest caveat is that these savings are projections, and group delivery trades something real, individual attention and intimacy, for throughput, with little outcome data yet on whether benefit survives the trade. The deeper unsolved questions are about the human element: how to train and supervise enough facilitators (a priority flagged even in the field’s ethics consensus, which named training and licensure as core[3]JAMA Network Open (2024), Banbury consensus: 20 points across 5 ethical issues including the training, education and licensure of practitioners), and how to standardise a psychological support process that is, by its nature, hard to pin down. The outlook is a field that knows its scalability problem intimately and has plausible but unproven solutions, with the workforce bottleneck, not the drug, as the rate-limiting step.

The implementation question pulls in an unusually practical mix of players: health systems and regulators designing the rules (Oregon, Australia’s TGA, the NHS), the clinics and training organisations building the delivery infrastructure, and the cost-bearers, insurers and governments, deciding what gets funded. The lessons emerging from the front line are sobering. Translating these therapies into ordinary community clinics has surfaced whole categories of challenge, from inadequate infrastructure to poor clinical practice, prompting calls for multidisciplinary oversight[1]Front Psychiatry (2021), translating to community clinics: five categories of challenge (risks, poor practice, infrastructure, perceptions, relationships); calls for a multidisciplinary advisory body, and even where a drug is cheap, access can stall: the affordability of generic ketamine has not translated into accessibility, with subsidy requests repeatedly rejected[2]Aust N Z J Psychiatry (2023), affordability analysis: generic racemic ketamine is about $5/dose vs $600-900 for branded esketamine; an ~AUD$100M subsidy request was rejected twice.

For an honest broker, implementation is where the field’s optimism meets its hardest practical limits, and the responsible posture is to take those limits seriously. The science of efficacy is advancing fast; the science of delivery is barely begun, resting on a handful of real-world cohorts, feasibility pilots, cost projections and service-model proposals rather than robust outcome data. The genuine risk is a two-tier reality, in which these therapies are delivered well to those who can pay and patchily, or not at all, to everyone else. The most useful framing keeps a clear distinction between "this works in a trial" and "we know how to provide this, at scale, affordably and equitably", credits the serious work on group models, training and real-world data, and is candid that the central problems, the workforce, the cost of the human therapy, the fidelity of delivery and the fairness of access, remain unsolved.